OTC Markets OTCID USD

Nymox Pharmaceutical Corporation (NYMXF)

0.0589 +0.0289 (+96.33%)

At close: October 30 at 4:00:00 PM EDT

Chart Range Bar

Loading chart for NYMXF

Previous Close 0.0300
Open 0.0200
Bid 0.0260 x 2843800
Ask 0.0600 x 1051000
Day's Range 0.0200 - 0.0300
52 Week Range 0.0002 - 0.1999
Volume 41,200
Avg. Volume 8,679
Market Cap (intraday) 6.187M
Beta (5Y Monthly) -9.19
PE Ratio (TTM) --
EPS (TTM) -0.0500
Earnings Date --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est --

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

nymox.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NYMXF

46.52%

S&P 500 (^GSPC)

10.73%

1-Year Return

NYMXF

44.43%

S&P 500 (^GSPC)

11.11%

3-Year Return

NYMXF

94.11%

S&P 500 (^GSPC)

81.91%

5-Year Return

NYMXF

96.69%

S&P 500 (^GSPC)

64.59%

Earnings Per Share (Normalized)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q4 FY13

Revenue 937.49k

Earnings --

Profit Margin 0.00%

FY12

FY13

-2M

-1M

-300.0%

-200.0%

-100.0%

0.0%

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-373.68%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-4.28M
Diluted EPS (ttm)

-0.0500

Balance Sheet and Cash Flow

Total Cash (mrq)

74k
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-665k

MATEF

JPPYY

GWTI

SCUPF

OMHI

U.S. markets closed

Nymox Pharmaceutical Corporation (NYMXF)

-1.83%

65.45%

-1.83%

46.52%

-44.43%

-96.69%

-99.07%

Nymox Pharmaceutical Corporation Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (Normalized)

Revenue vs. Earnings

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch